SG11202002186VA - Novel artificial nucleic acid molecules - Google Patents

Novel artificial nucleic acid molecules

Info

Publication number
SG11202002186VA
SG11202002186VA SG11202002186VA SG11202002186VA SG11202002186VA SG 11202002186V A SG11202002186V A SG 11202002186VA SG 11202002186V A SG11202002186V A SG 11202002186VA SG 11202002186V A SG11202002186V A SG 11202002186VA SG 11202002186V A SG11202002186V A SG 11202002186VA
Authority
SG
Singapore
Prior art keywords
nucleic acid
acid molecules
artificial nucleic
novel artificial
novel
Prior art date
Application number
SG11202002186VA
Other languages
English (en)
Inventor
Thomas Schlake
Andreas Thess
Moritz Thran
Frédéric Chevessier-Tünnesen
Marion Pönisch
Original Assignee
Curevac Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2018/057552 external-priority patent/WO2018172556A1/en
Application filed by Curevac Ag filed Critical Curevac Ag
Publication of SG11202002186VA publication Critical patent/SG11202002186VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SG11202002186VA 2017-10-19 2018-10-17 Novel artificial nucleic acid molecules SG11202002186VA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP2017076775 2017-10-19
EP2017076741 2017-10-19
PCT/EP2018/057552 WO2018172556A1 (en) 2017-03-24 2018-03-23 Nucleic acids encoding crispr-associated proteins and uses thereof
EP2018076185 2018-09-26
PCT/EP2018/078453 WO2019077001A1 (en) 2017-10-19 2018-10-17 NEW ARTIFICIAL NUCLEIC ACID MOLECULES

Publications (1)

Publication Number Publication Date
SG11202002186VA true SG11202002186VA (en) 2020-05-28

Family

ID=66173912

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002186VA SG11202002186VA (en) 2017-10-19 2018-10-17 Novel artificial nucleic acid molecules

Country Status (13)

Country Link
US (1) US20220233568A1 (cg-RX-API-DMAC7.html)
EP (1) EP3697912A1 (cg-RX-API-DMAC7.html)
JP (4) JP7863957B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250138817A (cg-RX-API-DMAC7.html)
CN (1) CN111630173A (cg-RX-API-DMAC7.html)
AU (2) AU2018351481B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020004351A2 (cg-RX-API-DMAC7.html)
CA (1) CA3073634A1 (cg-RX-API-DMAC7.html)
IL (2) IL321714A (cg-RX-API-DMAC7.html)
MX (2) MX2020003995A (cg-RX-API-DMAC7.html)
RU (1) RU2020115287A (cg-RX-API-DMAC7.html)
SG (1) SG11202002186VA (cg-RX-API-DMAC7.html)
WO (1) WO2019077001A1 (cg-RX-API-DMAC7.html)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2841572B1 (en) 2012-04-27 2019-06-19 Duke University Genetic correction of mutated genes
SG11201506052PA (en) 2013-02-22 2015-09-29 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
US10676726B2 (en) 2015-02-09 2020-06-09 Duke University Compositions and methods for epigenome editing
WO2017066497A2 (en) 2015-10-13 2017-04-20 Duke University Genome engineering with type i crispr systems in eukaryotic cells
US12214054B2 (en) 2015-11-30 2025-02-04 Duke University Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
WO2017109134A1 (en) 2015-12-22 2017-06-29 Curevac Ag Method for producing rna molecule compositions
US12612654B2 (en) 2016-02-12 2026-04-28 CureVac SE Method for analyzing RNA
EP3423595A1 (en) 2016-03-03 2019-01-09 CureVac AG Rna analysis by total hydrolysis
EP3443081A4 (en) 2016-04-13 2019-10-30 Duke University CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
JP7490211B2 (ja) 2016-07-19 2024-05-27 デューク ユニバーシティ Cpf1に基づくゲノム編集の治療適用
MX2019011215A (es) 2017-03-24 2020-02-12 Curevac Ag Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
EP3625363A1 (en) 2017-05-17 2020-03-25 CureVac Real Estate GmbH Method for determining at least one quality parameter of an rna sample
US11602557B2 (en) 2017-08-22 2023-03-14 Cure Vac SE Bunyavirales vaccine
SG11202003247RA (en) 2017-11-08 2020-05-28 Curevac Ag Rna sequence adaptation
US11931406B2 (en) 2017-12-13 2024-03-19 CureVac SE Flavivirus vaccine
CN111511928A (zh) 2017-12-21 2020-08-07 库瑞瓦格股份公司 偶联到单一支持物或标签的线性双链dna和用于制备所述线性双链dna的方法
US12509492B2 (en) 2018-01-19 2025-12-30 Duke University Genome engineering with CRISPR-Cas systems in eukaryotes
EP3773702A2 (en) * 2018-04-05 2021-02-17 CureVac AG Novel yellow fever nucleic acid molecules for vaccination
CA3091558A1 (en) 2018-04-17 2019-10-24 Curevac Ag Novel rsv rna molecules and compositions for vaccination
CA3102135A1 (en) 2018-06-28 2020-01-02 Curevac Ag Bioreactor for rna in vitro transcription
TW202039534A (zh) 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
CA3122645A1 (en) 2018-12-21 2020-06-25 Curevac Ag Methods for rna analysis
TWI887234B (zh) 2019-04-14 2025-06-21 美國公爵大學 治療杜興氏(duchenne)肌肉失養症之大型突變熱點之aav載體介導之刪除
CN110241116B (zh) * 2019-05-21 2023-02-07 中国医学科学院放射医学研究所 一种环状rna及在促进dna损伤修复中的应用
EP3986452A1 (en) 2019-06-18 2022-04-27 CureVac AG Rotavirus mrna vaccine
EP4007814A1 (en) * 2019-07-26 2022-06-08 Akouos, Inc. Methods of treating hearing loss using a secreted target protein
WO2021028439A1 (en) 2019-08-14 2021-02-18 Curevac Ag Rna combinations and compositions with decreased immunostimulatory properties
JP2022546417A (ja) * 2019-08-29 2022-11-04 チューリッヒ大学 最小mRNAおよびその使用
AU2020371697A1 (en) * 2019-10-22 2022-05-26 Genevant Sciences Gmbh Ornithine transcarbamylase (OTC) constructs and methods of using the same
CN110592223B (zh) * 2019-10-31 2022-10-25 中南大学湘雅三医院 一种NSCLC的诊断和预后标记物hsa_circRNA_012515的应用
CN112759652B (zh) * 2019-11-01 2022-09-20 北京华夏清医治疗科技有限公司 一种嵌合抗原受体及其应用
US12606822B2 (en) * 2019-11-07 2026-04-21 Icahn School Of Medicine At Mount Sinai Synthetic modified RNA and uses thereof
CN111041025B (zh) 2019-12-17 2021-06-18 深圳市瑞吉生物科技有限公司 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法
CA3162019A1 (en) 2019-12-20 2021-06-24 Gemma NAVARRO Lipid nanoparticles for delivery of nucleic acids
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
DE202021004130U1 (de) 2020-02-04 2022-10-26 Curevac Ag Coronavirus-Vakzine
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US20230096704A1 (en) * 2020-02-05 2023-03-30 University Of Florida Research Foundation, Incorporated Rna-loaded nanoparticles and use thereof for the treatment of cancer
AU2021247163A1 (en) * 2020-04-01 2022-10-20 University Of Florida Research Foundation, Incorporated Multilamellar RNA nanoparticle vaccine against SARS-CoV-2
CN111413498B (zh) * 2020-04-08 2023-08-04 复旦大学附属中山医院 一种肝细胞肝癌的自身抗体7-AAb检测panel及其应用
WO2021239880A1 (en) 2020-05-29 2021-12-02 Curevac Ag Nucleic acid based combination vaccines
CN111744019B (zh) * 2020-07-01 2023-08-04 深圳瑞吉生物科技有限公司 基于甘露糖的mRNA靶向递送系统及其应用
US20220017971A1 (en) * 2020-07-15 2022-01-20 Kookmin University Industry Academy Cooperation Foundation Composition for predicting chemotherapy resistance of ovarian cancer and use thereof
EP4172194A1 (en) 2020-07-31 2023-05-03 CureVac SE Nucleic acid encoded antibody mixtures
WO2022028559A1 (en) * 2020-08-07 2022-02-10 The Hong Kong University Of Science And Technology Compositions and methods for increasing protein expression
CN116635525A (zh) * 2020-08-21 2023-08-22 北京大学 环状rna疫苗及其使用方法
WO2022043551A2 (en) 2020-08-31 2022-03-03 Curevac Ag Multivalent nucleic acid based coronavirus vaccines
WO2022076901A1 (en) * 2020-10-09 2022-04-14 Duke University Novel targets for reactivation of prader-willi syndrome-associated genes
CN112280750B (zh) * 2020-10-22 2022-11-01 山东农业大学 具有跨种传播能力的新型鹅星状病毒及其应用
CN112526127B (zh) * 2020-10-28 2022-12-06 四川大学华西医院 一种破伤风抗原的检测方法及其应用
US20240299309A1 (en) 2020-12-22 2024-09-12 CureVac SE Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
MX2023007574A (es) 2020-12-22 2023-09-29 CureVac SE "vacuna de arn contra variantes de sars-cov-2.
CN112574997B (zh) * 2021-01-17 2023-07-21 楷拓生物科技(苏州)有限公司 一种fbxw7环状rna的改构体及其在肿瘤药物和新冠疫苗中的应用
CA3170747A1 (en) 2021-01-27 2022-08-04 Moritz THRAN Method of reducing the immunostimulatory properties of in vitro transcribed rna
JP7894875B2 (ja) * 2021-02-12 2026-07-24 シアトル チルドレンズ ホスピタル ディー/ビー/エイ シアトル チルドレンズ リサーチ インスティテュート 熱ショックタンパク質90結合ドメインを有する活性誘導型融合タンパク質
EP4313152A1 (en) 2021-03-26 2024-02-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
EP4312988A2 (en) 2021-03-31 2024-02-07 CureVac SE Syringes containing pharmaceutical compositions comprising rna
CN113341152B (zh) * 2021-04-27 2022-04-26 华南农业大学 Rps9蛋白在食蟹猴超数排卵良好应答预测中的应用
CA3171589A1 (en) 2021-05-03 2022-11-03 Moritz THRAN Improved nucleic acid sequence for cell type specific expression
EP4377331A2 (en) 2021-07-30 2024-06-05 CureVac SE Mrnas for treatment or prophylaxis of liver diseases
AU2021461416A1 (en) 2021-08-24 2024-02-22 BioNTech SE In vitro transcription technologies
IL309502A (en) 2021-09-03 2024-02-01 CureVac SE Lipid nanoparticles for nucleic acid delivery involving phosphatidylserine
EP4763287A2 (en) 2021-09-03 2026-06-24 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
WO2023144193A1 (en) 2022-01-25 2023-08-03 CureVac SE Mrnas for treatment of hereditary tyrosinemia type i
CN115029349B (zh) * 2022-06-09 2024-11-12 中国农业大学 与植物抗病性相关的circRNA、来源基因及其应用
CA3260237A1 (en) 2022-06-24 2023-12-28 Tune Therapeutics, Inc. Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression
AU2023310896A1 (en) 2022-07-19 2025-01-30 Shenzhen Shenxin Biotechnology Co., Ltd. Mrna for sars-cov-2 s protein and use thereof
CA3267272A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Biologicals Sa FLU VIRUS VACCINES
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
CN115606550B (zh) * 2022-10-28 2024-01-12 陆华 一种自身免疫性甲状腺炎诱导的卵巢储备功能低下动物模型的构建方法
WO2024098360A1 (zh) * 2022-11-11 2024-05-16 斯微(上海)生物科技股份有限公司 人工核酸分子
TW202430633A (zh) * 2022-12-07 2024-08-01 科羅拉多大學董事會法人團體 新穎的hiv-1變異體及其在動物激發模型中的使用方法
US20260209719A1 (en) 2022-12-16 2026-07-23 Shenzhen Shenxin Biotechnology Co., Ltd. Utr for improving translation efficiency and/or stability of rna molecule and use thereof
IL322426A (en) 2023-01-31 2025-09-01 Synplogen Co Ltd Artificial synthetic nucleic acid for enhancing protein expression
WO2024160936A1 (en) 2023-02-03 2024-08-08 Glaxosmithkline Biologicals Sa Rna formulation
GB202302092D0 (en) 2023-02-14 2023-03-29 Glaxosmithkline Biologicals Sa Analytical method
CN116240175B (zh) * 2023-02-28 2024-02-23 武汉科技大学 一种嵌合抗hiv广谱中和抗体外泌体的制备方法以及在抗hiv感染中的应用
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
WO2024188312A1 (en) * 2023-03-16 2024-09-19 The Hong Kong University Of Science And Technology Compositions and methods for enhanced protein expression
EP4701657A1 (en) 2023-04-27 2026-03-04 GlaxoSmithKline Biologicals S.A. Influenza virus vaccines
JP2026518411A (ja) 2023-04-27 2026-06-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザウイルスワクチン
AU2024271830A1 (en) * 2023-05-12 2025-11-27 Seqirus Inc. Vaccine adjuvants
EP4713483A1 (en) 2023-05-16 2026-03-25 CureVac RNA Printer GmbH Improved rna in vitro transcription using dna beads
WO2025027060A1 (en) * 2023-07-31 2025-02-06 CureVac SE Nucleic acid encoded runx3 transcription factor
WO2025040263A1 (en) 2023-08-24 2025-02-27 CureVac Manufacturing GmbH Purification process for in vitro amplified dna
JP2025082576A (ja) * 2023-11-17 2025-05-29 アンジェス株式会社 核酸、医薬組成物、及び核酸を製造する方法
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation
CN122180503A (zh) 2024-04-30 2026-06-09 深圳深信生物科技有限公司 脂质纳米颗粒及其应用
WO2025246436A1 (en) * 2024-05-29 2025-12-04 Therorna Inc. Circular rna-based therapeutic vaccine for treating hpv positive cancer
WO2026115169A1 (en) * 2024-11-29 2026-06-04 Corequest Sagl Gene delivery to cells of vectors comprising crat nucleotidic or aminoacidic sequences
CN121800306B (zh) * 2026-01-21 2026-08-11 南昌航空大学 一种双功能固体酸材料催化六氟磷酸根水解方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA2258125C (en) 1996-06-14 2010-11-23 Meiji Milk Products Co., Ltd. T-cell epitope peptides
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
US7060284B1 (en) 1999-08-03 2006-06-13 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
ATE291925T1 (de) 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
JP2010507361A (ja) 2006-07-31 2010-03-11 キュアバック ゲーエムベーハー 具体的には免疫刺激剤/アジュバントとしての、一般式(I):GlXmGn、または一般式(II):ClXmCnで表される核酸
WO2008017517A1 (en) 2006-08-11 2008-02-14 Life Sciences Research Partners Vzw Immunogenic peptides and their use in immune disorders
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
EP3100718B1 (en) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
JP5721441B2 (ja) 2008-01-31 2015-05-20 キュアバック ゲーエムベーハーCurevac Gmbh 免疫賦活剤/アジュバントとしての式(I)(NuGlXmGnNv)aで表される核酸分子及びその誘導体
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
AU2009303345B2 (en) 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
EP3699172A3 (en) 2008-11-10 2020-11-18 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
WO2010087791A1 (en) 2009-01-27 2010-08-05 Utc Power Corporation Distributively cooled, integrated water-gas shift reactor and vaporizer
EP2391343B1 (en) 2009-01-29 2017-03-01 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
CA3042927C (en) 2009-05-05 2022-05-17 Arbutus Biopharma Corporation Lipid compositions for the delivery of therapeutic agents
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
CN104922071A (zh) 2010-04-09 2015-09-23 帕西拉制药有限公司 用于配制大直径合成膜囊泡的方法
EP4481047A3 (en) 2010-06-03 2025-04-16 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
EP2449113B8 (en) 2010-07-30 2015-11-25 CureVac AG Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
RS63890B1 (sr) 2010-08-31 2023-02-28 Glaxosmithkline Biologicals Sa Mali lipozomi za isporuku rnk koja kodira imunogen
JP5911870B2 (ja) 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするrnaの送達のためのpeg化リポソーム
EP3542789A3 (en) 2010-08-31 2020-01-01 GlaxoSmithKline Biologicals SA Lipids suitable for liposomal delivery of protein-coding rna
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
RU2014104090A (ru) 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
RU2658490C2 (ru) 2012-03-27 2018-06-21 Кьюрвак Аг Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов
ES2660129T3 (es) * 2012-03-27 2018-03-20 Curevac Ag Moléculas de ácido nucleico artificiales que comprenden un 5'UTR-TOP
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
SG11201506052PA (en) 2013-02-22 2015-09-29 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
PL3019619T3 (pl) * 2013-07-11 2022-01-10 Modernatx, Inc. Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania
AU2014310932B2 (en) 2013-08-21 2019-06-06 CureVac SE Composition and vaccine for treating lung cancer
BR112016003361A2 (pt) 2013-08-21 2017-11-21 Curevac Ag vacina do vírus sincicial respiratório (rsv)
CN105517569A (zh) 2013-08-21 2016-04-20 库瑞瓦格股份公司 狂犬病疫苗
BR112016000889A2 (pt) 2013-08-21 2017-12-12 Curevac Ag composição e vacina para tratamento de câncer de próstata
AU2014375402B2 (en) * 2013-12-30 2020-10-01 CureVac SE Artificial nucleic acid molecules
CA2935878C (en) 2014-03-12 2023-05-02 Curevac Ag Combination of vaccination and ox40 agonists
WO2015149944A2 (en) 2014-04-01 2015-10-08 Curevac Gmbh Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
HRP20220070T1 (hr) * 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
CA2962849A1 (en) 2014-12-16 2016-06-23 Curevac Ag Ebolavirus and marburgvirus vaccines
BR112017009835A2 (pt) * 2014-12-30 2017-12-26 Curevac Ag moléculas de ácido nucleico artificiais
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
EP4239080A3 (en) * 2015-07-01 2023-11-01 CureVac Manufacturing GmbH Method for analysis of an rna molecule
US12258567B2 (en) * 2015-08-28 2025-03-25 CureVac SE Artificial nucleic acid molecules
WO2017081110A1 (en) 2015-11-09 2017-05-18 Curevac Ag Rotavirus vaccines
EP3374504B1 (en) 2015-11-09 2025-03-19 CureVac SE Optimized nucleic acid molecules
WO2017109134A1 (en) 2015-12-22 2017-06-29 Curevac Ag Method for producing rna molecule compositions
WO2017140905A1 (en) 2016-02-17 2017-08-24 Curevac Ag Zika virus vaccine
WO2018104540A1 (en) * 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
MX2019011215A (es) * 2017-03-24 2020-02-12 Curevac Ag Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.

Also Published As

Publication number Publication date
KR20200071081A (ko) 2020-06-18
JP2026090405A (ja) 2026-06-02
AU2025200901A1 (en) 2025-02-27
KR102858623B1 (ko) 2025-09-10
JP2021501572A (ja) 2021-01-21
WO2019077001A1 (en) 2019-04-25
AU2018351481B2 (en) 2025-04-03
EP3697912A1 (en) 2020-08-26
IL272850A (en) 2020-04-30
JP7863957B2 (ja) 2026-05-22
AU2018351481A1 (en) 2020-03-12
US20220233568A1 (en) 2022-07-28
KR20250138817A (ko) 2025-09-22
RU2020115287A (ru) 2021-11-19
JP2024012523A (ja) 2024-01-30
CN111630173A (zh) 2020-09-04
JP2025131658A (ja) 2025-09-09
RU2020115287A3 (cg-RX-API-DMAC7.html) 2022-02-28
IL321714A (en) 2025-08-01
MX2026002469A (es) 2026-04-01
BR112020004351A2 (pt) 2020-09-08
MX2020003995A (es) 2020-07-22
CA3073634A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
IL272850A (en) Artificial nucleic acid molecules
SG11201911430PA (en) Novel nucleic acid molecules
SG10201913629VA (en) Artificial nucleic acid molecules
IL278000B (en) Synthetic nucleic acid transcripts
SG11201704681QA (en) Artificial nucleic acid molecules
PT4023755T (pt) Moléculas de ácido nucleico artificiais para uma expressão melhorada de proteína
SG11202000764RA (en) Nucleic acid molecules and uses thereof
IL277472A (en) Nucleic acid molecules for pseudouridylation
IL254000A0 (en) Nucleic acid sequence composition
EP3472359A4 (en) Nucleic Acid Sequencing
GB201507119D0 (en) Nucleic Acid Construct
EP3157573A4 (en) Alternative nucleic acid molecules and uses thereof
EP3157572A4 (en) Alternative nucleic acid molecules and uses thereof
SG11201603144QA (en) Artificial nucleic acid molecules
GB201507115D0 (en) Nucleic Acid Construct
GB201521858D0 (en) Small molecules
SG11201610168YA (en) Nucleic acid synthesis techniques
GB201507111D0 (en) Nucleic acid construct
EP3159409A4 (en) Antisense nucleic acid
EP3118311A4 (en) Antisense nucleic acid
GB201507104D0 (en) Nucleic acid construct
HUE045086T2 (hu) Szachariddal módosított nukleinsav molekulák
GB201507108D0 (en) Nucleic acid construct
ZA202001649B (en) Rna molecules
GB201608197D0 (en) Novel proteins